[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]

October 2018 - April 2015

Decade

Year

Issue

October 2018, Vol 4, No. 10, Pages 1311-1439

Original Investigation

Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor–Positive, HER2-Negative Early Breast CancerA Secondary Analysis of the BIG 1-98 Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. 2018;4(10):1335-1343. doi:10.1001/jamaoncol.2018.1778

This secondary analysis of a randomized clinical trial examines the association between driver alterations and the risk of mutations and prognosis in women with postmenopausal hormone receptor–positive, HER2-negative breast cancer.

Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate CancerA Phase 2 Clinical Trial

Abstract Full Text
JAMA Oncol. 2018;4(10):1344-1351. doi:10.1001/jamaoncol.2018.2168

This phase 2 clinical trial investigates the safety and efficacy of BIND-014, a docetaxel-containing nanoparticle targeting prostate-specific membrane antigen, for treating patients with metastatic castration-resistant prostate cancer.

Association of Exercise With Mortality in Adult Survivors of Childhood Cancer

Abstract Full Text
has active quiz
JAMA Oncol. 2018;4(10):1352-1358. doi:10.1001/jamaoncol.2018.2254

This cohort analysis examines the association between self-reported exercise and change in exercise and mortality in adult survivors of childhood cancer.

Effect of a Lay Health Worker Intervention on Goals-of-Care Documentation and on Health Care Use, Costs, and Satisfaction Among Patients With CancerA Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. 2018;4(10):1359-1366. doi:10.1001/jamaoncol.2018.2446

This randomized clinical trial tests the effect of consultation with a lay health worker on documentation of goals of care and health care use, costs, and satisfaction among patients with advanced-stage or recurrent cancer at a Veterans Affairs medical center.

Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor–Positive, HER2-Negative Advanced Breast CancerThe BOLERO-6 Randomized Clinical Trial

Abstract Full Text
open access
JAMA Oncol. 2018;4(10):1367-1374. doi:10.1001/jamaoncol.2018.2262

This randomized clinical trial compares treatment with everolimus plus exemestane vs everolimus or capecitabine monotherapy for estrogen receptor-positive, HER2-negative advanced breast cancer.

Complementary Medicine, Refusal of Conventional Cancer Therapy, and Survival Among Patients With Curable Cancers

Abstract Full Text
JAMA Oncol. 2018;4(10):1375-1381. doi:10.1001/jamaoncol.2018.2487

This cohort study compares overall survival, treatment adherence, and patient characteristics among patients with cancer receiving conventional cancer treatment with vs without complementary medicine.

Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600–Mutated Metastatic MelanomaPooled Analysis of 4 Randomized Clinical Trials

Abstract Full Text
open access
JAMA Oncol. 2018;4(10):1382-1388. doi:10.1001/jamaoncol.2018.2668

This exploratory recursive partitioning analysis modeled associations between prespecified covariates and survival outcomes using pooled data from 4 randomized clinical trials of adult patients with BRAF V600–mutated metastatic melanoma treated with dacarbazine, vemurafenib, or cobimetinib plus vemurafenib.

Maintenance Treatment and Survival in Patients With MyelomaA Systematic Review and Network Meta-analysis

Abstract Full Text
has audio
JAMA Oncol. 2018;4(10):1389-1397. doi:10.1001/jamaoncol.2018.2961

This systematic review and network meta-analysis analyzes and compares different maintenance regimens for treating patients with newly diagnosed multiple myeloma and associated progression-free and overall survival.

Association of Low-Fat Dietary Pattern With Breast Cancer Overall SurvivalA Secondary Analysis of the Women’s Health Initiative Randomized Clinical Trial

Abstract Full Text
online only
JAMA Oncol. 2018;4(10):e181212. doi:10.1001/jamaoncol.2018.1212

This secondary analysis of the Women’s Health Initiative randomized clinical trial investigates the association of a low-fat dietary pattern vs a usual diet comparison with overall survival among women with breast cancer.

Brief Report

Targetable Alterations in Adult Patients With Soft-Tissue SarcomasInsights for Personalized Therapy

Abstract Full Text
JAMA Oncol. 2018;4(10):1398-1404. doi:10.1001/jamaoncol.2018.0723

This study examines the use of next-generation sequencing for identification of potentially actionable alterations in patients with soft-tissue sarcoma.

Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and TemozolomideAn Analysis From the NRG Oncology/RTOG 0424 Trial

Abstract Full Text
JAMA Oncol. 2018;4(10):1405-1409. doi:10.1001/jamaoncol.2018.1977

This secondary analysis of the NRG Oncology/RTOG 0424 randomized clinical trial examines the proportion of patients with MGMT promoter methylation and its association with survival outcomes in high-risk glioma treated with radiotherapy and temozolomide.

Use and Effectiveness of Adjuvant Endocrine Therapy for Hormone Receptor–Positive Breast Cancer in Men

Abstract Full Text
online only
JAMA Oncol. 2018;4(10):e181114. doi:10.1001/jamaoncol.2018.1114

This cohort study using data from the US National Cancer Database assesses the patterns of use and the effectiveness of adjuvant endocrine therapy for hormone receptor–positive breast cancer in men.

Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins

Abstract Full Text
online only
JAMA Oncol. 2018;4(10):e182078. doi:10.1001/jamaoncol.2018.2078

This validation study investigates the use of circulating protein biomarkers to improve lung cancer risk assessment and eligibility criteria for screening with low-dose computed tomography.

Research Letter

Assessment of Challenges Encountered by Dutch Oncologists When Patients Ask for Second Opinions

Abstract Full Text
JAMA Oncol. 2018;4(10):1425-1426. doi:10.1001/jamaoncol.2018.3495

This analysis of interviews with Dutch oncologists investigates the outcomes of second-opinion requests for physician-patient and physician-colleague relationships.

Financial Conflicts of Interest Among Oncologist Authors of Reports of Clinical Drug Trials

Abstract Full Text
JAMA Oncol. 2018;4(10):1426-1428. doi:10.1001/jamaoncol.2018.3738

This analysis investigates the prevalence of financial relationships between oncologist authors of clinical drug trials and the pharmaceutical industry and how often such financial interests are unreported.

Review

Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia

Abstract Full Text
JAMA Oncol. 2018;4(10):1413-1420. doi:10.1001/jamaoncol.2018.1915

This narrative review discusses the pathophysiology of adult acute lymphoblastic leukemia and recent progress in the development of personalized therapies.

JAMA Oncology Clinical Challenge

A Mass With High Uptake of Fluorodeoxyglucose on Positron Emission Tomography

Abstract Full Text
JAMA Oncol. 2018;4(10):1421-1422. doi:10.1001/jamaoncol.2018.1120

An adolescent girl presented with a painless mass in the right thigh and high uptake of fluorodeoxyglucose on positron emission tomography. What is your diagnosis?

Viewpoint

Bridging the Critical Divide in Pain Management Guidelines From the CDC, NCCN, and ASCO for Cancer Survivors

Abstract Full Text
JAMA Oncol. 2018;4(10):1323-1324. doi:10.1001/jamaoncol.2018.1574

This Viewpoint discusses the Centers for Disease Control and Prevention guidelines for prescribing opioids for chronic pain and how they may cause confusion for oncology clinicians.

Expert Review of Breast Pathology in Borderline LesionsA Chance to Reduce Overdiagnosis and Overtreatment?

Abstract Full Text
JAMA Oncol. 2018;4(10):1325-1326. doi:10.1001/jamaoncol.2018.1953

This Viewpoint discusses how expert review of breast pathology in borderline lesions may offer the opportunity to reduce overdiagnosis and overtreatment of breast cancer.

Ethical Implications of Direct-to-Consumer Hereditary Cancer Tests

Abstract Full Text
JAMA Oncol. 2018;4(10):1327-1328. doi:10.1001/jamaoncol.2018.2439

This Viewpoint examines the ethics of informed consent and test result disclosure associated with direct-to-consumer genetic testing for hereditary cancer susceptibility.

From The JAMA Network

Redefining the Value Proposition of Precision OncologyCan We Integrate Genomic Testing Without Overselling It?

Abstract Full Text
JAMA Oncol. 2018;4(10):1423-1424. doi:10.1001/jamaoncol.2018.3729

This commentary discusses a cohort study of patients with non–small cell lung cancer published in JAMA that compares clinical outcomes following broad-based genomic sequencing vs routine testing for EGFR mutations and/or ALK mutations.

Editorial

PIK3CA Mutations in Hormone Receptor–Positive Breast CancersPIKing Biomarkers to Inform Adjuvant Endocrine Therapy Decisions

Abstract Full Text
JAMA Oncol. 2018;4(10):1330-1332. doi:10.1001/jamaoncol.2018.1766
Cancer Care Chronicles

Sisu—The Ability to Keep Fighting After Most Would Quit

Abstract Full Text
JAMA Oncol. 2018;4(10):1329. doi:10.1001/jamaoncol.2018.1571

This article discusses the bravery of an elderly cancer patient from Finland who had sisu, a Finnish word to describe ferocity and tenacity.

Comment & Response

Regarding the Congruence Between 2 Circulating Tumor DNA Sequencing Assays

Abstract Full Text
JAMA Oncol. 2018;4(10):1428-1429. doi:10.1001/jamaoncol.2018.2311

Regarding the Congruence Between 2 Circulating Tumor DNA Sequencing Assays

Abstract Full Text
JAMA Oncol. 2018;4(10):1429. doi:10.1001/jamaoncol.2018.2314

Regarding the Congruence Between 2 Circulating Tumor DNA Sequencing Assays

Abstract Full Text
JAMA Oncol. 2018;4(10):1429-1430. doi:10.1001/jamaoncol.2018.2317

Regarding the Congruence Between 2 Circulating Tumor DNA Sequencing Assays

Abstract Full Text
JAMA Oncol. 2018;4(10):1430. doi:10.1001/jamaoncol.2018.2320

Regarding the Congruence Between 2 Circulating Tumor DNA Sequencing Assays

Abstract Full Text
JAMA Oncol. 2018;4(10):1430-1431. doi:10.1001/jamaoncol.2018.2323

Regarding the Congruence Between 2 Circulating Tumor DNA Sequencing Assays—Reply

Abstract Full Text
JAMA Oncol. 2018;4(10):1431-1432. doi:10.1001/jamaoncol.2018.2326

Analytical Validity and Clinical Utility of Tumor Biomarkers

Abstract Full Text
JAMA Oncol. 2018;4(10):1432. doi:10.1001/jamaoncol.2018.1698

Understanding the Limitations of Cancer Registry Insurance Data—Implications for Policy

Abstract Full Text
JAMA Oncol. 2018;4(10):1432-1433. doi:10.1001/jamaoncol.2018.2436

Understanding the Limitations of Cancer Registry Insurance Data—Implications for Policy—Reply

Abstract Full Text
JAMA Oncol. 2018;4(10):1433-1434. doi:10.1001/jamaoncol.2018.2460

Risk of Breast Implant–Associated Anaplastic Large Cell Lymphoma

Abstract Full Text
JAMA Oncol. 2018;4(10):1434. doi:10.1001/jamaoncol.2018.2616

Risk of Breast Implant–Associated Anaplastic Large Cell Lymphoma

Abstract Full Text
JAMA Oncol. 2018;4(10):1434-1435. doi:10.1001/jamaoncol.2018.2619

Risk of Breast Implant–Associated Anaplastic Large Cell Lymphoma—Reply

Abstract Full Text
JAMA Oncol. 2018;4(10):1435. doi:10.1001/jamaoncol.2018.2624

Underutilization of Combined-Modality Therapy in Limited-Stage Small Cell Lung Cancer

Abstract Full Text
JAMA Oncol. 2018;4(10):1435-1436. doi:10.1001/jamaoncol.2018.3261

Underutilization of Combined-Modality Therapy in Limited-Stage Small Cell Lung Cancer—Reply

Abstract Full Text
JAMA Oncol. 2018;4(10):1436-1437. doi:10.1001/jamaoncol.2018.3292

Improving on Tail-of-the-Curve Evaluation With the American Society of Clinical Oncology Value Framework

Abstract Full Text
JAMA Oncol. 2018;4(10):1437. doi:10.1001/jamaoncol.2018.3264

Improving on Tail-of-the-Curve Evaluation With the American Society of Clinical Oncology Value Framework

Abstract Full Text
JAMA Oncol. 2018;4(10):1437-1438. doi:10.1001/jamaoncol.2018.3289

Improving on Tail-of-the-Curve Evaluation With the American Society of Clinical Oncology Value Framework—Reply

Abstract Full Text
JAMA Oncol. 2018;4(10):1438-1439. doi:10.1001/jamaoncol.2018.3295

Inconsistent Reporting of Potential Conflicts of Interest

Abstract Full Text
JAMA Oncol. 2018;4(10):1439. doi:10.1001/jamaoncol.2018.3461
Correction

Missing Conflict of Interest Disclosure

Abstract Full Text
free access
JAMA Oncol. 2018;4(10):1439. doi:10.1001/jamaoncol.2018.4091

Incorrect Author Surname

Abstract Full Text
free access
JAMA Oncol. 2018;4(10):1439. doi:10.1001/jamaoncol.2018.4576

Missing Names of Co–Senior Authors

Abstract Full Text
free access
JAMA Oncol. 2018;4(10):1439. doi:10.1001/jamaoncol.2018.4985
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2018;4(10):1316. doi:10.1001/jamaoncol.2017.3252
In This Issue of JAMA Oncology

Highlights

Abstract Full Text
free access
JAMA Oncol. 2018;4(10):1311. doi:10.1001/jamaoncol.2017.3251
×